Clinical trial Recruiting at 1 site Interventional Ages 19 and up

Recovery of hypothyroidism caused by immune checkpoint inhibitors after stopping treatment

Official title: SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial

Run by Seoul National University Bundang Hospital · NCT07421869 · Data updated 2026-11-12

This trial will test whether adults who developed hypothyroidism while on immune checkpoint inhibitors can stop levothyroxine after those cancer drugs are stopped.

More Hypothyroidism trials

Quick facts

Study typeInterventional
Ages19 Years and up
SexAll
Enrollment107 (estimated)
SponsorSeoul National University Bundang Hospital
Academic / other
Drugs / interventionsradiation
Locations1 site (Seongnam-si)
StatusRecruiting
StartedJune 12, 2024
Main results expectedMarch 4, 2029
Study endsMarch 4, 2029
Registry record updatedFebruary 19, 2026
Trial IDNCT07421869 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥19 years) who developed hypothyroidism while receiving ICIs, started levothyroxine, have already stopped ICI therapy, and are currently taking less than 0.1 mg levothyroxine are ideal candidates.

Probably not a fit

Patients with prior thyroid surgery, radioactive iodine or neck radiation, those still on high-dose levothyroxine (≥0.1 mg), or those still receiving ICIs are unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study enrolls adults who developed hypothyroidism during immune checkpoint inhibitor (ICI) therapy, have discontinued ICIs, and are taking levothyroxine. Participants will undergo a stepwise levothyroxine taper every three months if thyroid function tests remain normal, with planned discontinuation if they maintain normal tests on a low dose (≤0.025 mg). Thyroid function tests and clinical symptoms will be monitored at each visit to detect recovery or relapse. The study will quantify the proportion of patients who can stop thyroid replacement and analyze clinical and laboratory factors that predict successful withdrawal.

Why it matters

Potential benefit: If successful, some patients may be able to stop long-term levothyroxine and avoid unnecessary lifelong thyroid replacement.

How similar studies have gone: Retrospective reports show that some patients recover thyroid function after stopping ICIs, but prospective, structured withdrawal data are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults aged 19 years or older.
* Patients with a history of treatment with immune checkpoint inhibitors (ICIs).
* Developed hypothyroidism during ICI treatment and initiated levothyroxine after starting ICI therapy.
* Discontinued ICI therapy prior to study enrollment.

Exclusion Criteria:

* Use of levothyroxine or antithyroid medications within 3 months prior to initiating ICI therapy.
* History of thyroid surgery, radioactive iodine therapy, or neck radiation therapy.
* Current levothyroxine dose ≥0.1 mg at the time of enrollment.

Where it's running

  • Department of Internal Medicine, Seoul National University Bundang Hospital
    Seongnam-si, South Korea
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.